Epoetin theta
Biopoin, Eporatio (epoetin theta) is a protein pharmaceutical. Epoetin theta was first approved as Biopoin on 2009-10-23. It has been approved in Europe to treat anemia, chronic kidney failure, and neoplasms.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| hemic and lymphatic diseases | D006425 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| retacrit | Biologic Licensing Application | 2022-07-19 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
523 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | 6 | 68 | 111 | 52 | 20 | 254 |
| Chronic renal insufficiency | D051436 | N18 | 4 | 7 | 19 | 6 | 8 | 44 | |
| Neoplasms | D009369 | C80 | — | 13 | 14 | 5 | 7 | 39 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 3 | 7 | 14 | 5 | 5 | 34 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 14 | 7 | 2 | — | 23 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | 4 | 8 | 15 |
| Lymphoma | D008223 | C85.9 | 1 | 2 | 7 | 1 | 1 | 12 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 6 | 1 | — | 8 |
| Drug therapy | D004358 | — | 2 | 1 | 3 | — | 6 | ||
| Fatigue | D005221 | HP_0012378 | R53.83 | — | 2 | 1 | 1 | 2 | 6 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | — | 3 | 7 | — | 1 | 11 | |
| Plasma cell neoplasms | D054219 | — | 2 | 5 | — | 1 | 8 | ||
| Cerebral palsy | D002547 | G80 | 1 | 2 | 1 | — | 3 | 7 | |
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 4 | 3 | 3 | — | — | 7 |
| Blood transfusion | D001803 | — | 4 | 5 | — | 1 | 7 | ||
| Orthopedic procedures | D019637 | — | 4 | 6 | — | — | 7 | ||
| Traumatic brain injuries | D000070642 | S06 | — | 3 | 4 | — | 1 | 6 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | 3 | — | 1 | 5 |
| Precancerous conditions | D011230 | — | 2 | 2 | — | — | 4 | ||
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 2 | 2 | — | — | 4 |
Show 57 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 11 | 3 | — | — | 2 | 14 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 5 | — | — | — | 5 |
| Reperfusion injury | D015427 | 1 | 1 | — | — | 1 | 3 | ||
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 2 | — | — | 1 | 3 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | 1 | 1 | — | — | 1 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 1 | — | — | — | 2 |
| Moyamoya disease | D009072 | EFO_0004250 | I67.5 | 1 | 1 | — | — | 1 | 2 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 2 | — | — | — | 2 |
| Replacement arthroplasty knee | D019645 | — | 1 | — | — | 1 | 2 | ||
| Chronic disease | D002908 | — | 1 | — | — | 1 | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
| Autoimmune hepatitis | D019693 | K75.4 | 1 | — | — | — | — | 1 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
| Alveolar bone loss | D016301 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
| Iron metabolism disorders | D019189 | E83.1 | — | — | — | — | 1 | 1 | |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | — | — | 1 | 1 |
| Uterine diseases | D014591 | N85.9 | — | — | — | — | 1 | 1 | |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Myocardial reperfusion injury | D015428 | EFO_0002687 | — | — | — | — | 1 | 1 | |
| Hemiarthroplasty | D062785 | — | — | — | — | 1 | 1 | ||
| Fibrosis | D005355 | — | — | — | — | 1 | 1 | ||
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EPOETIN THETA |
| INN | epoetin alfa |
| Description | Epoetin theta, sold under the brand name Biopoin among others, is a copy of the human hormone erythropoietin.
|
| Classification | Protein |
| Drug class | erythropoietins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 762263-14-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108290 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 64FS3BFH5W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,968 documents
View more details
Safety
Black-box Warning
Black-box warning for: Retacrit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
35,598 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more